I
rritable bowel syndrome (IBS) is a functional bowel disorder that commonly presents in primary care and has an array of symptoms including abdominal discomfort and altered bowel habit. There may be an overlap of symptoms with other gastrointestinal disorders, leading to difficulty or delay in diagnosis. The condition can produce a variety of troublesome physical and psychological sequelae causing significant impact on an individual's quality of life. The aim of this article is to highlight the ways in which IBS can present to the General Practitioner and guide the approach to investigation, diagnosis and management in primary care.
The GP curriculum and irritable bowel syndrome Clinical module 3.13: Digestive health requires GPs to: . Recognise that digestive problems are common in general practice
. Have a central role in the diagnosis and management of digestive problems in primary care
. Recognise that dyspepsia, gastro-oesophageal reflux disease and irritable bowel disease are common conditions, affecting a significant proportion of the population
Overview

Epidemiology
Irritable bowel syndrome (IBS) is a chronic and relapsing gastrointestinal disorder that is characterised by abdominal discomfort and altered bowel habit (British Medical Journal, 2018 ; National Institute for Health and Care Excellence (NICE), 2017a). It remains one of the most common bowel pathologies that presents to both primary and secondary care, and may manifest with a variety of symptoms; some of which, due to their sensitive nature, patients may be hesitant to disclose (Ford, 2012) . It is estimated that between 10 and 20% of the UK population suffers from IBS (British Medical Journal, 2018) with a similar global incidence of the condition despite lifestyle differences between countries (Spiller et al., 2007) . However, the true prevalence of the condition is thought to be higher, as many people do not present to physicians with their symptoms (Harding and Huins, 2014) .
IBS has been found to be up to twice as common in females than males, and shows a peak prevalence in the third and fourth decades of life (NICE, 2017b) . Gender variability is observed between subtypes of IBS (Harding and Huins, 2014) . Approximately one-in-five people are affected by IBS in their lifetime, and 30% of people will develop symptoms of IBS following an episode of acute bacterial gastroenteritis (Ford, 2012) .
IBS has been found to significantly impact quality of life, work productivity and social functioning in people with the condition (Chey et al., 2015) . It is associated with poor coping strategies, as well as mood disturbance (Harding and Huins, 2014) .
Aetiology
The definitive cause of IBS remains unclear, and it is most likely to be of multi-factorial origin (British Medical Journal, 2018) . There is thought to be linked with abnormalities in smooth muscle activity, gastrointestinal motility dysfunction and visceral sensation (Harding and Huins, 2014) . IBS is thought to have a genetic component, as first-degree relatives of those with the condition are twice as likely to be affected (Spiller et al., 2007) . Other important factors in the development of IBS include psychological, immune and dietary components (British Medical Journal, 2018) .
Traditionally, IBS has been divided into three main subtypes based on predominance of bowel habit, using the Rome IV subtyping criteria (see Table 1 ) (Spiller et al., 2007) . Classification is subcategorised into predominance of constipation, diarrhoea, or mixed stool pattern, as well as 'unspecified IBS' where indiscrete symptoms cannot allow for sufficient categorisation (Harding and Huins, 2014) . Although this may be useful for classification and research purposes, IBS is now considered a spectrum of these three subtypes, depending on the severity and quantity of each person's different symptoms rather than three distinct disorders (NICE, 2017b) .
Presentation: Symptoms and signs
IBS is defined by abdominal discomfort or pain associated with alteration of bowel habit. Symptoms must persist for at least 6 months and occur in the absence of structural abnormalities (Spiller et al., 2007) . IBS symptoms may be intermittent or continuous, with bowel dysfunction presenting as being either predominantly constipation, diarrhoea or mixed patterns. Abdominal pain in IBS is often relieved by defecation (NICE, 2017a) . People with IBS will often describe a 'morning rush' sensation; an urge to pass motion several times on waking and around breakfast (Harding and Huins, 2014) .
Other common symptoms associated with IBS include abdominal bloating, nausea, dyspepsia and early satiety. Symptoms may be aggravated by the ingestion of food, and there can be episodes of mucus passed rectally (NICE, 2017a) .
IBS can also present with extra-intestinal symptoms, including headaches, backache, dyspareunia and urinary symptoms (Harding and Huins, 2014) . The variety of presentations means that IBS symptoms often overlap with other gastrointestinal disorders, such as coeliac disease and dyspepsia. This can make diagnosis difficult (NICE, 2017b) .
Rates of anxiety and depression are higher in people suffering with IBS. Psychological disturbance has been found to be a more common primary reason for consultation rather than gastrointestinal symptoms. Furthermore, the chronic symptoms of IBS may be precipitated by stress, leading to acute worsening of symptoms (Harding and Huins, 2014) .
Physical examination is likely to be normal in IBS. Assessment should include abdominal examination (palpation of the abdomen is likely to be unremarkable, except for mild lower abdominal tenderness), assessment of body mass index and rectal or pelvic examination with the person's consent (NICE, 2017b) . Specific history points may guide the need for further examination.
Diagnosis and investigation
There is no specific test to confirm the diagnosis of IBS, and it should no longer be considered as a diagnosis of exclusion (Harding and Huins, 2014) . Instead, IBS should be diagnosed using the presence of 'positive' symptom-based criteria (see Table 2 ) (NICE, 2017a). Specifically, symptoms of abdominal pain, either relieved by defecation or associated with altered bowel habits, and the presence of two further symptoms from Table 2 must have been present for a minimum of 6 months (Harding and Huins, 2014) .
Investigations must be decided upon based on an individual's predominant symptoms, clinical examination findings, or the presence of red flag features (see Box 1) in order to rule out an alternative organic disease (NICE, 2017a). Careful assessment is required for patients over the age of 50 years and presenting with IBS-like symptoms, in order to rule out significant underlying pathology. However, recent research indicates that IBS has a significant prevalence in older generations (British Medical Journal, 2018) . Referral should be initiated using the NICE guidelines on recognition and referral for suspected cancer where appropriate (see Box 1) or to a gastroenterologist if there is suspicion of an underlying inflammatory bowel disorder (Harding and Huins, 2014) .
Useful investigations include stool culture (in cases of prolonged loose stools), colonoscopy (particularly where lower gastrointestinal symptoms predominate) and hydrogen breath testing in persistent dyspepsia. The following tests are helpful . Full blood count (to assess for anaemia or active inflammation)
. Coeliac screen (due to an overlap of presenting symptoms)
. Ca-125 tumour marker (particularly in women with predominantly diarrhoea or bloating to rule out ovarian cancer)
. Fecal calprotectin (for those with symptoms that may be due to inflammatory bowel disease)
Management
Following a diagnosis, patients with IBS should be provided with information about their disorder and its symptoms, in order to improve understanding and symptom-control outcomes through self-help methods (Spiller et al., 2007) . Resources include patient information leaflets from NHS Choices or the charities Guts UK and the IBS network. Management of IBS can be broken down into lifestyle factors, pharmacotherapy and psychological therapies. A patient-centered approach is advocated, in order to optimise a person's individual symptoms and psychosocial situation (NICE, 2017a).
Lifestyle and diet
Management of IBS should initially include first-line dietary and lifestyle advice, with an emphasis on the importance of self-help in effectively managing symptoms (NICE, 2017b) . Simple dietary advice to reduce IBS-related symptoms includes the importance of taking regular meals and avoiding long gaps between eating. Ideally, alcohol and fizzy drink consumption should be reduced in addition to a restriction to no more than three cups of tea or coffee per day. It is advised that high-fibre foods and resistant starches, which are found in processed foods and fresh fruits, are limited to three portions per day. Sorbitol should be avoided if diarrhoea is a predominant feature, whereas oats and linseeds should be recommended for flatulence. Soluble fibre may be advocated for those with predominant constipation or conversely avoided in patients with diarrhoea (Harding and Huins, 2014) . Insoluble fibres including bran, however, should be avoided by all patients with IBS (NICE, 2017a).
Evidence has shown that increasing physical activity improves IBS symptoms (Harding and Huins, 2014) . The use of the General Practice Activity Questionnaire tool has been advocated to assess for, and subsequently encourage, patients with low exercise levels to become more active through brief advice (Department of Health and Social Care, 2013) . Furthermore, the identification and management of associated stress, anxiety and depression are likely to benefit IBS symptoms (NICE, 2017a).
Pharmacology
The choice of pharmacotherapy is individualised to target a person's predominant symptoms, such as constipation or diarrhoea, bloating or abdominal cramps, and should be issued alongside dietary and lifestyle advice (Harding and Huins, 2014) .
Antispasmodics, such as hyoscine, should be used for the management of abdominal pain and spasms, as they have been found to be more effective than placebo (De Wit et al., 2011) . It is postulated that these medications work by reducing smooth muscle spasm and affect visceral hypersensitivity (Chang, 2014) . Peppermint oil is also an effective alternative for managing bloating and spasm in IBS (Ford et al., 2008b) .
In diarrhoea-predominant IBS, the opioid receptor agonist Loperamide may be used to prolong gut transit time and lead to a reduction in faecal volume (NICE, 2017a) . Bulk-forming laxatives may be used in constipation-predominant IBS, as they contain soluble fibre that leads to retention of fluid and subsequent stimulation of peristalsis. Lactulose should be avoided in IBS-related constipation, due to a possible increase in gas production and exacerbation of IBS symptoms (NICE, 2017b) . Linaclotide may be considered for patients with IBS if constipation has been present for at least 12 months and has failed to respond to optimal doses of standard bulk-forming laxatives (Harding and Huins, 2014) . If commenced, patients should be re-assessed following a 3-month trial of Linaclotide to measure response. All patients on laxative or anti-motility agent treatment for their respective symptoms should be educated regarding titration of their medication based on stool consistency, with the aim of achieving Bristol Stool Form Scale type 4 (NICE, 2017a).
Antidepressant medications have been shown to be effective in the management of IBS (Spiller et al., 2007) . As a result, NICE advocates the use of a low-dose tricyclic antidepressant (for example, once daily Amitriptyline 10 mg which may be titrated up to 30 mg per day) as a second-line treatment for IBS if there has been no reported improvement in symptoms with laxatives, loperamide or antispasmodics (Harding and Huins, 2014) . The use of a selective serotonin reuptake inhibitor is only advocated by NICE if low-dose tricyclic antidepressants have not been effective (NICE, 2017a) .
Referral in IBS
Patients may be referred to a dietician for consideration of exclusion diets if symptoms persist despite first-line dietary and lifestyle advice (NICE, 2017a (Harding and Huins, 2014) . Referral for psychological therapies, such as cognitive behavioural therapy, can be considered for patients with IBS whose symptoms have not responded to other interventions after a year (Spiller et al., 2007) . Acupuncture and reflexology are not routinely advocated (Harding and Huins, 2014) . Referral to a gastroenterologist should be considered if symptoms persist despite optimal primary care management or if there is diagnostic uncertainty (NICE, 2017b).
Prognosis
It is important that patients are reassured that IBS does not increase long-term risk of serious pathology (NICE, 2017b) . IBS is likely to follow a chronic relapsing and remitting trajectory with more than half of people still experiencing symptoms 7 years after their initial diagnosis (Harding and Huins, 2014) . Prognosis is variable, with some longitudinal studies finding that up to 38% of patients had an improvement in their IBS symptoms at 2 years (NICE, 2017a).
KEY POINTS
. IBS is a chronic, relapsing gastrointestinal disorder that is characterised by abdominal pain or discomfort associated with defecation or change in bowel habit
. IBS is defined by symptom-based criteria in the absence of detectable organic causes or red flag symptoms; it does not increase long-term risk of serious pathology
. Open questions should be used to assess for sensitive symptoms such as faecal incontinence
. First-line management of IBS symptoms involves dietary and lifestyle advice with further intervention based on an individual's predominant symptoms
. IBS has a significant negative impact on quality of life and social functioning in many patients
. Referral to dieticians, gastroenterologists or psychologists may be required for refractory symptoms or where there is diagnostic uncertainty
